Neurology

Author response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease


We thank Dr. Ashford for his comment on our article “INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.”1 Dr. Ashford raises 2 important points: whether a gamma-secretase-modifying (GSM) NSAID such as ibuprofen would likely have given different results and whether the Alzheimer progression score outcome was sufficiently precise to reveal efficacy.

Source link

Related posts

Developmental Milestones That Lead to Academic Success: From Age 6-10

Newsemia

Fremanezumab May Offer Prevention for Refractory Migraine

Newsemia

Predictors of cognitive functioning after carotid revascularization

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy